Pancreatic KRAS Vaccine Misses Its Primary Endpoint
Randomized Phase 2 AMPLIFY-7P did not meet its prespecified intent-to-treat disease-free survival endpoint for camupepimut after pancreatic cancer treatment (HR 0.85). Favorable subgroup and adjusted estimates are hypothesis generating and cannot override the failed…
